GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neos Therapeutics Inc (NAS:NEOS) » Definitions » Book Value per Share

Neos Therapeutics (Neos Therapeutics) Book Value per Share : $-0.41 (As of Sep. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Neos Therapeutics Book Value per Share?

Neos Therapeutics's book value per share for the quarter that ended in Sep. 2020 was $-0.41.

During the past 3 years, the average Book Value Per Share Growth Rate was -6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Neos Therapeutics was 67.90% per year. The lowest was -68.60% per year. And the median was -6.80% per year.

Neos Therapeutics's current price is $1.15. Its book value per share for the quarter that ended in Sep. 2020 was $-0.41. Hence, today's PB Ratio of Neos Therapeutics is .

During the past 7 years, the highest P/B Ratio of Neos Therapeutics was 144.00. The lowest was 0.00. And the median was 12.87.


Neos Therapeutics Book Value per Share Historical Data

The historical data trend for Neos Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neos Therapeutics Book Value per Share Chart

Neos Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Book Value per Share
Get a 7-Day Free Trial 4.89 -0.10 0.31 0.16 -0.12

Neos Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.12 -0.27 -0.33 -0.41

Competitive Comparison of Neos Therapeutics's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Neos Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neos Therapeutics's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neos Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Neos Therapeutics's PB Ratio falls into.



Neos Therapeutics Book Value per Share Calculation

Neos Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2019 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.13-0.00)/49.73
=-0.12

Neos Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2020 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-20.55-0.00)/49.76
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Neos Therapeutics  (NAS:NEOS) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Neos Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Neos Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neos Therapeutics (Neos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2940 N. Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
Executives
Alan L Heller director BAXTER INTERNATIONAL INC ONE BAXTER PKWY DF2-2W DEERFIELD IL 60015
Gregory J Robitaille director
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Linda M Szyper director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Gerald W. Mclaughlin director, officer: Chief Executive Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John M Limongelli officer: SVP & General Counsel 700 PENNSYLVANIA DRIVE, EXTON PA 19341
Thomas P Mcdonnell officer: Chief Commercial Officer C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Vipin K Garg officer: Chief Executive Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Dorothy Engelking officer: VP, Regulatory Affairs C/O NEOS THERAPEUTICS, INC. 2940 N. HIGHWAY 360 GRAND PRAIRIE TX 75050
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Juergen Martens officer: Chief Tech/Operations Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355